GlobeNewswire Clinical StudiesOriginal article
Optimi Health to Initiate Phase 2 Clinical Trial Evaluating Psilocybin-Assisted Therapy for Major Depressive Disorder
Phase 2PsilocybinPositive
AI Analysis
Summary
Optimi Health will initiate a Health Canada-authorized Phase 2 clinical trial evaluating psilocybin-assisted therapy for major depressive disorder, with dosing completion expected by end of 2027.
Clinical Trial Data
Phase
Phase 2
Importance:5/10
Sentiment:
0.50
psilocybinmajor depressive disorderclinical trialHealth Canadapsychedelic
Related Companies
Read the original article
Published by GlobeNewswire Clinical Studies on September 10, 2026 12:45 PM